Supriya Lifescience Limited (BOM:543434)
India · Delayed Price · Currency is INR 620.45
+1.35 (0.22%)
At close: Apr 21, 2026
Supriya Lifescience Revenue
Supriya Lifescience had revenue of 2.06B INR in the quarter ending December 31, 2025, with 11.20% growth. This brings the company's revenue in the last twelve months to 7.35B, up 9.68% year-over-year. In the fiscal year ending March 31, 2025, Supriya Lifescience had annual revenue of 6.96B with 22.12% growth.
Revenue (ttm)
7.35B
Revenue Growth
+9.68%
P/S Ratio
6.79
Revenue / Employee
14.28M
Employees
515
Market Cap
49.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 6.96B | 1.26B | 22.12% |
| Mar 31, 2024 | 5.70B | 1.09B | 23.73% |
| Mar 31, 2023 | 4.61B | -691.11M | -13.04% |
| Mar 31, 2022 | 5.30B | 1.39B | 35.49% |
| Mar 31, 2021 | 3.91B | 712.17M | 22.26% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Unichem Laboratories | 22.14B |
| FDC Limited | 20.78B |
| Sanofi India | 18.37B |
| Viyash Scientific | 18.17B |
| Morepen Laboratories | 17.87B |
| Hikal | 17.46B |
| Procter & Gamble Health | 13.49B |
| CORONA Remedies | 13.44B |